Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)

v3.20.2
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)
12 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of outstanding warrants

The following is a summary of the Company’s outstanding warrants at March 31, 2020:

  

Warrants     Exercise       Expiration       Intrinsic Value at  
Outstanding     Price ($)       Date       March 31, 2020  
1 (1)    1,171,875.00       April 26, 2021     $ —   
3 (2)    195,312.50       September 12, 2022       —   
32 (3)    12,187.50       May 24, 2023       —   
36                   $ —   

  

(1) Warrants issued in connection with the sale of convertible notes. The warrants were exercisable on the grant date (April 26, 2016) and remain exercisable until April 26, 2021.
(2) Warrants issued in connection with funding. The warrants were exercisable on the grant date (September 12, 2017) and remain exercisable until September 12, 2022.
(3) Warrants issued in connection with a Severance Agreement with Richard N. Azar II, the Company’s former Chief Executive Officer. The warrants were exercisable on the grant date (May 25, 2018) and remain exercisable until May 24, 2023.